The prognosis of rhabdomyosarcoma is closely related to age, primary tumor location, tumor size, and tumor type, so for advanced rhabdomyosarcoma, do not give up lightly if family conditions allow, and there is hope for improvement after active treatment. With the application of targeted drugs in soft tissue sarcoma, it brings new hope to advanced rhabdomyosarcoma, so rhabdomyosarcoma needs to be given standardized and comprehensive treatment to improve the prognosis. Rhabdomyosarcoma is a rare malignant tumor, most common among soft tissue sarcomas in children. It develops from abnormally growing early muscle cells and can occur in various parts of the body, commonly in the head and neck, extremities, and genitourinary organs, and can be classified as embryonal rhabdomyosarcoma, adenoid rhabdomyosarcoma, and pleomorphic or mesenchymal rhabdomyosarcoma. The clinical manifestations of rhabdomyosarcoma are painless or painful masses at the primary site, which are prone to distant metastases in advanced stages, including lung, liver, bone, bone marrow, and brain. If rhabdomyosarcoma develops to advanced stage, it can be treated by current comprehensive treatments such as surgery, chemotherapy and radiotherapy, and the 5-year survival rate can reach more than 70%, and the survival rate varies in different risk groups, with the 5-year survival rate of 70%-90% in the low-risk group, 50%-70% in the intermediate-risk group, and 20%-30% in the high-risk group.